A phase III trial of savolitinib combination with Tagrisso for the treatment of non-small cell lung cancer (T790M-/c-Met+) patients.

Trial Profile

A phase III trial of savolitinib combination with Tagrisso for the treatment of non-small cell lung cancer (T790M-/c-Met+) patients.

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2016

At a glance

  • Drugs Osimertinib (Primary) ; Savolitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 02 Aug 2016 According to Chi-Med media release, company targets to initiate this pivotal registration study before the end of H1 2017.
    • 22 Jun 2016 New trial record
    • 20 Jun 2016 According to a Chi-Med media release, the company plans to initiate this trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top